Search Results
Jan 26, 2026, 13:34 ET Endocrinologist-Designed AI Nutrition App Launches to Bring Clarity to Eating in the GLP-1 Era
insights for people managing GLP-1 use, diabetes, PCOS, and menopause.LOS ANGELES, Jan. 26, 2026 /PRNewswire/ -- At a time when millions of people are turning to GLP-1 medications and weight-loss apps
More news about: Caloria
Jan 26, 2026, 09:00 ET FuturHealth Expands Its Suite of Wellness Solutions With the Addition of the Wegovy® Pill
The first FDA-approved oral GLP-1 pill is now available to new and existing FuturHealth membersSAN DIEGO, Jan. 26, 2026 /PRNewswire/ --
More news about: FuturHealth
Jan 26, 2026, 09:00 ET BIOSeedin Winter Innovation Partnering Summit：J.P.Morgan Spotlight
discussions on key topics such as accelerating clinical trial processes with AI technology and asset deployment strategies in the context of the GLP-1 market transformation.In the final autoimmune panel, speakers shared challenges and success stories of Sino-foreign collaborations, discussing
More news about: bioSeedin
Jan 26, 2026, 05:00 ET Pepzyme AG™ Supercharges Collagen Breakdown for GLP-1 Support
activity, supporting the body's natural GLP-1 activity and complementing GLP-1 therapies.This transforms collagen into a functional ingredient that supports both the metabolic and structural challenges facing GLP-1 users—from impaired protein digestion to accelerated
More news about: Specialty Enzymes & Probiotics
Jan 25, 2026, 19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
NCT07321678) with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026.
More news about: Ascletis Pharma Inc.
Jan 25, 2026, 19:10 ET 歌禮宣佈口服小分子GLP-1R激動劑ASC30治療糖尿病的13周美國II期研究完成首批受試者給藥
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1rasc3013ii-302669404.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Jan 23, 2026, 11:40 ET PMMI Pharma Infographic Reveals Manufacturing and Regulatory Challenges as Well as Future Packaging Trends
remote)"Breakthrough new drugs such as specialized oncology treatments as well as new applications for existing drugs — like GLP-1 prescriptions for weight management — are leading the charge on industry growth," says Jorge Izquierdo, vice president, market development at PMMI.Although
More news about: PMMI, The Association for Packaging and Processing Technologies
Jan 22, 2026, 16:00 ET Lofta and Accomplish Health to Collaborate in Expanding Access to Medical Weight Loss for Millions of Sleep Apnea Patients
Regular virtual visits with obesity-trained physicians and advanced practice clinicians, ii) FDA-approved anti-obesity medications, including GLP-1 therapies when clinically appropriate, iii) Nutrition coaching from expert registered dietitians, and iv) Remote monitoring tools, such as connected
More news about: Lofta
Jan 22, 2026, 08:01 ET CoreAge Rx Introduces Flat-Rate Pricing for GLP-1 Medications
management solutions, today announced a pricing structure designed to eliminate hidden fees and provide predictable costs for patients seeking GLP-1 medications. The company now offers compounded semaglutide starting at $99 per month when paid annually and compounded tirzepatide at $149 per month
More news about: CoreAge Rx
Jan 21, 2026, 09:00 ET Dueling Pressures Push Employers to Reinvent Their Benefits Strategy
employers for GLP-1 coverage."GLP-1s have created two markets: diabetes care with clear clinical justification and weight management where coverage decisions vary," said Kim Bell, EVP, head of Health and Benefits, NFP. "When nearly a third of employees say GLP-1 coverage could
More news about: NFP Corp.
Jan 21, 2026, 09:00 ET Rightway Eliminates Hidden Conflicts and Loopholes of Traditional PBM Pricing with SureSpend™
reporting that delivers expensive surprises. Meanwhile, PMPM guarantees include exclusion lists that remove entire drug categories, such as vaccines and GLP-1s, from protection, capped refunds that expose clients to unlimited liability, shared savings clauses that allow PBMs to keep a portion of under-budget
More news about: Rightway
Jan 21, 2026, 09:00 ET Benepass Raises $40M Series B to Help Employers Redesign Benefits for Rising Healthcare Costs
are projected to rise by as much as 10 percent this year, driven by increased utilization, chronic conditions, and specialty drugs such as GLP-1 medications.1 At the same time, more than a quarter of employers are shifting costs to employees through higher premiums and
More news about: Benepass
Jan 21, 2026, 08:44 ET IMAGE Skincare Welcomes Back Co-Founder Dr. Marc Ronert as Chief Executive Officer
skincare innovation formulated for those who've experienced facial skin concerns after rapid weight loss using a GLP-1/GIP – frequently referred to as "Ozempic Face". Drawing from his background in aesthetic medicine, Dr. Ronert was instrumental in guiding the product's
More news about: IMAGE Skincare
Jan 21, 2026, 05:47 ET Matthew DelMauro, MD Observes Rise in Plastic Surgery at his NYC Practice Following GLP-1-Related Weight Loss
board-certified plastic surgeon, is reporting a noticeable increase in patients seeking plastic surgery after significant weight loss associated with GLP-1 medications. While these medications have helped many individuals achieve dramatic weight reduction, Dr. DelMauro notes that rapid or substantial
More news about: Matthew DelMauro, MD
Jan 20, 2026, 17:52 ET CoreAge Rx Expands GLP-1 Access to Support New Year Weight Loss Goals
leading telehealth pharmacy specializing in personalized medication services, today announced a strategic New Year's expansion of its compounded GLP-1 weight management program. The expansion provides increased access to compounded tirzepatide and semaglutide, perfectly timed to support Americans
More news about: CoreAge Rx
Jan 20, 2026, 10:55 ET Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel
regulatory, DEA enforcement, Board of Pharmacy compliance, and pharmaceutical IP matters. Her expertise includes 503A and 503B compounding (including GLP-1s and peptides), DSCSA compliance, recalls, clinical trial management, labeling and advertising review, and submissions ranging from 510(k) to PMA applications.Dr.
More news about: Health Law Alliance
Jan 20, 2026, 09:00 ET Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman
FDA-approved uses for Ozempic® and how this differentiates this iconic brand from other GLP-1s for the treatment of type 2 diabetes and unapproved compounded "semaglutide.""Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic® is
More news about: Novo Nordisk
Jan 20, 2026, 08:38 ET Cobalt Benefits Group Partners with Navion to Strengthen Pharmacy Benefit Management and Deliver Cost Savings for Employers
Through the Cobalt/Navion model, groups gain access to:Clinical programs such as biosimilar-first strategies, GLP-1 management, and independent prior authorization reviewExpanded value levers, including patient assistance, international sourcing,
More news about: Cobalt Benefits Group
Jan 20, 2026, 05:00 ET 歌禮選定新一代每月一次皮下注射GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
[1] GLP-1R：胰高血糖素樣肽-1受體，GIPR：葡萄糖依賴性促胰島素多肽受體，GCGR：胰高血糖素受體 關於歌禮製藥有限公司歌禮製藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial
More news about: 歌禮製藥有限公司
Jan 20, 2026, 04:00 ET Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Jan 19, 2026, 08:48 ET ZERO SUGAR LO SECCO Prosecco Launches New Consumer Website, Expands U.S. Distribution; Now Available in Eight Markets and Shipping Nationally
at a pivotal moment as consumers recognize that zero sugar Prosecco can align with modern lifestyles, including low-carb, keto, and GLP-1–influenced approaches, without compromising quality or enjoyment," Elling said. "We're proud to partner with distributors who understand that wellness
More news about: LO SECCO PROSECCO
Jan 16, 2026, 16:01 ET MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Jan 16, 2026, 09:01 ET Sunlight.com Survey: 4 in 10 Overweight Americans Say They'll Try a GLP-1 Pill in 2026
having taken a GLP-1 for weight loss. This includes 39% who say they are currently taking a GLP-1 and 10% who say they previously took one but stopped.For non-users, injections are a key obstacle. Among those who have never taken a GLP-1 for weight loss, 30%
More news about: Sunlight
Jan 16, 2026, 09:00 ET More Protein for the New Year and New Better-for-You
As reported by Circana, 23% or an estimated 30 million U.S. Households, are using GLP1 medications to lose weight or treat diabetes, and these consumers are seeking more Protein in their diet in an effort to live a healthier lifestyle.Fortunately,
More news about: Ellsworth Cooperative Creamery
Jan 15, 2026, 12:00 ET Reality TV Star Heather Gay and Atkins Flip the Script on Weight Wellness for GLP-1 Users
while on GLP-1s and is easy to tolerate. It provides a tested, convenient solution at-the-ready to help GLP-1 users manage nutrition levels and support their success on the drugs.Key Findings:The Atkins tailored eating approach may help GLP-1 users
More news about: Simply Good Foods Co.